Drug Metabolism, Distribution and Metabolite Identification

Phase I includes reactions such as oxidation, reduction and hydrolysis. CYP enzymes catalyse many oxidative reactions, while esterases and other enzymes have separate roles. Metabolism occurs in the liver and other tissues; not every transformation is a liver CYP reaction.

Important CYP families include CYP3A, CYP2D6, CYP2C9, CYP2C19, CYP1A2 and CYP2B6, among others. Their contribution is substrate-specific. A list claiming that one enzyme handles every member of a therapeutic class is too broad.

Inhibition and induction can alter exposure to a parent and its metabolites. The direction of clinical effect also depends on whether the parent, an active metabolite or both contribute. Inhibiting formation of an active metabolite can reduce one effect even while the parent concentration rises.

Codeine conversion to morphine and tramadol conversion to O-desmethyltramadol illustrate CYP2D6-dependent activation. The products are different; tramadol is not converted into morphine. Genotype, medicines and other factors can change the balance of parent and metabolite.

Do not predict a fixed concentration or fatal outcome from a genotype and a standard dose. Current prescribing restrictions and pharmacogenetic recommendations must be consulted for clinical use. A forensic genotype result contributes to an assessment rather than proving the cause of an unexplained death.

Drug-interaction tables identify examples within a defined evidence framework. They are not complete lists of every interaction or a basis for assuming that an inhibitor makes every co-administered substrate toxic. Actual dosing, timing, organ function and other pathways matter.

Phase II includes glucuronidation, sulphation, glutathione conjugation, acetylation and other reactions. These can increase suitability for elimination, but not every product is inactive or more water-soluble in every meaningful context. Conjugation can occur directly on a parent compound.

Morphine forms morphine-3-glucuronide and morphine-6-glucuronide. M6G has opioid activity. Calling M3G simply inert can be misleading because non-analgesic effects have been investigated. Renal function and handling of metabolites can affect the overall clinical picture.

Paracetamol is cleared through several pathways, including conjugation. A smaller oxidative pathway produces the reactive metabolite NAPQI, normally handled through protective processes including glutathione. Excessive exposure can overwhelm protection and cause liver injury; one fixed dose does not predict every person's outcome.

Acetylation by NAT2 affects drugs such as isoniazid, with relevant individual variation. Genotype is one contributor alongside dose, disease and other exposures.

Laboratory preparation can alter conjugates. Hydrolysed and unhydrolysed assays can therefore measure different quantities. A report stating “total morphine” should make clear what the method includes, rather than treating it as directly interchangeable with unconjugated morphine.

6-monoacetylmorphine, also called 6-acetylmorphine or 6-MAM, is associated with heroin/diamorphine. Its validated identification adds specificity beyond morphine alone, which has several possible sources. Diamorphine also has legitimate medical uses in some jurisdictions, so the marker does not establish illicit intent.

6-MAM can be lost through metabolism or specimen change. Its absence does not exclude exposure, and a positive result does not prove that administration occurred within one exact number of minutes. Matrix, storage and the assay's capability affect detection.

Benzoylecgonine is an important cocaine-related target. Its interpretation depends on the specimen and method because metabolism, chemical conversion and contamination can contribute to patterns. A metabolite name does not automatically eliminate every alternative explanation.

Methadone and EDDP provide another parent–metabolite relationship. Finding both can support an exposure interpretation, but their ratio is affected by metabolism, timing and the specimen. It is not a standalone test of adherence, dose or a recent exact administration time.

Metabolites can be toxicologically important. Formate contributes to methanol injury; glycolate and oxalate are relevant in ethylene glycol poisoning. Oxalate crystals are supportive with alternative causes, not a unique proof of ethylene glycol exposure.

Some drugs share metabolites. Oxazepam, for example, can reflect more than one benzodiazepine pathway or direct administration. A full pattern and medication history are more informative than assuming every detected metabolite identifies only one parent.

Apparent volume of distribution relates the amount of drug in the body to a specified measured concentration under the pharmacokinetic model. It can exceed anatomical body volumes because a low plasma concentration can coexist with extensive tissue distribution.

Dose divided by an extrapolated initial concentration is a special model-based estimate, not the universal definition for every route or time point. Bioavailability and distribution phases matter. A single post-mortem blood concentration cannot be multiplied by a textbook Vd to reconstruct a swallowed dose.

For an appropriate simple first-order model, half-life is approximately 0.693 × Vd/clearance. Multi-compartment behaviour, nonlinear kinetics and time-varying physiology can limit a direct application. High Vd alone does not guarantee one particular terminal half-life.

After death, tissue release, diffusion, degradation and local contamination can alter results. PMR is not solely the inevitable consequence of high Vd. Sampling site, interval, specimen condition and the compound's properties all influence the measurement.

Peripheral and central blood should be separately identified when collected. A central-to-peripheral difference can support investigation of post-mortem effects, but neither ratio nor the lower result uniquely reconstructs antemortem blood. Peripheral specimens can also change.

Vitreous, urine, bile, tissue and hair add different information. Bile containing metabolites does not automatically prove chronic use, and gastric findings do not precisely timestamp ingestion. Interpret each matrix using an appropriate method and reference context.

A ratio reflects formation and elimination as well as dose pattern, route, genetic variation, interactions, organ function and specimen timing. In urine it also reflects excretion and accumulation over time. The same numerical ratio can arise through different histories.

Repeated dosing can overlap earlier parent and metabolite contributions. A single acute dose is not always a high-parent/low-metabolite pattern at collection. Post-mortem change and analytical hydrolysis can further alter the quantities being compared.

Before interpreting a ratio, confirm that both results are reliable and refer to compatible quantities. A denominator below a reporting or quantitative limit cannot be treated as an exact small number. Free and total measurements or different matrices should not be combined without justification.

Codeine-to-morphine ratios can inform hypotheses, but a greater-than-one rule does not uniquely identify codeine as the sole source or exclude every heroin/diamorphine exposure. Medication, timing, genotype and other findings are necessary context.

An apparent metabolite pattern also does not determine administration route by itself. A heroin-associated marker supports a parent-source hypothesis but does not distinguish injection, smoking and other routes. Scene and clinical evidence may address route separately.

When a ratio is used, state its assumptions and plausible alternatives. An honest interpretation can support one explanation more than another without claiming a precise clock or excluding every competing scenario.

Report parent and relevant metabolite findings when they answer the case question and fall within the method's scope. Not every assay needs every possible metabolite or an uninformative ratio. Explain why the chosen targets matter.

Therapeutic, toxic and fatal concentration data describe populations and circumstances. Their ranges can overlap. Tolerance is variable and incomplete; it should not be expressed as a universal five-to-twentyfold increase in a lethal threshold.

Co-exposures can modify effect through pharmacokinetic interactions or combined pharmacodynamic effects. Simply adding parent and metabolite mass concentrations is not always a valid measure of total toxicity because potency, binding and units can differ.

In US work, relevant ASB standards support validation, identification and report content. UKIAFT guidance provides a UK professional framework. India, Canada, Australia and other jurisdictions apply their relevant requirements; legal conclusions need their own foundation.

Preserve the distinction between chemical finding, exposure interpretation and cause-of-death opinion. A metabolite can add strong evidence while leaving source, dose, consent or responsibility unresolved. An informative report communicates that strength and its limits together.

Related reading: Factors Affecting the Intensity of Poisoning.

Related reading: Gases and Volatile Poisons: CO, Cyanide, Methanol, Ethanol.

Related reading: Acidic, Neutral and Alkaline Drug Analysis.